New Data and Acquisition Yield Strong EOY, Promising Q1

The disease-modifying capacity of Amarantus BioScience's lead therapeutic candidate, MANF, has been significantly validated by recent pre-clinical studies demonstrating that MANF inhibits neurological deterioration in Parkinson's disease (PD). These findings corroborate the potential of MANF as first-in-class curative therapy for PD, which is critically needed. Currently used medications only alleviate patient symptoms and do not function to reverse or stop disease progression.

Additionally, Amarantus has recently announced the acquisition of Neurodegenerative Diagnostic's intellectual property portfolio, which includes diagnostics for PD and ALS – further positioning the company as an emerging player in the field of neurological disorders.

Identified by Amarantus' proprietary bioengineering and drug discovery platform, MANF is a biological protein that stabilizes the nervous system in the body and has been found to have a striking ability to save neurons from cell death when disease conditions were presented. The present studies described show that key clinical hallmarks in an animal model of PD are significantly improved by MANF, but not by GDNF, a therapeutic protein currently in Phase II clinical trials, once developed by Amgen and now in trials through MedGenesis Therapeutix.

Specifically, research performed at UCLA's School of Medicine shows that MANF improves behavioral deficits by approximately 50% four weeks post-treatment, with a 35% improvement seen as early as two weeks post-treatment. In contrast, GDNF did not provide any improvement in behavioral deficits at any time point assayed. In a separate study performed at Neuroscience Associates, MANF was shown to actually increase the density of neurons in the brain by approximately 14%, whereas GDNF treatment showed no benefits in maintaining neuron density. Finally, a third study performed at PharmaNet shows that MANF treatment produces a 100% increase in dopamine concentration within the brain. Dopamine is a neurotransmitter produced in the brain that is required for neurological health, and decreased dopamine is a major etiological factor underlying PD and a primary target for therapeutic stabilization. GDNF was found to have no effect on dopamine concentration in the brain.

Collectively, these data show that MANF: has potent curative properties that stops/or reverses the progression of PD; improves behavior, the fundamental treatment goal of PD therapeutics; increases the density of neurons in the brain, which are significantly decreased in PD; and increases the concentration of dopamine in the brain, which decreases in PD and serves a major etiological factor underlying the disease.

The acquisition of Neurodegenerative Diagnostic's intellectual property has also significantly leveraged Amarantus. In this transaction Amarantus took ownership of 20 pending patent applications covering a variety of biomarkers and assays related to the treatment of various neurological disorders including Parkinson's, Alzheimer's, and ALS, as well as patent applications related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia. These technologies provide an invaluable addition to Amarantus' intellectual property estate, which integrates seamlessly with and supports the company's therapeutic platform.

Amarantus is currently preparing Phase 2 clinical trials for the acquired NuroPro Parkinson's Disease blood test, which serves as a diagnostic for early detection of PD.

Amarantus Bioscience

OTCBB: AMBS
52 wk: $0.08-0.10
February 4: $0.09
Mkt Cap: ~$19MM

Founded: 2008

View the company's presentation during OneMedForumSF 2013 on January 8th, 2013

Gerald E. Commissiong, President & CEO

Board of Directors:

Robert L. Harris, Director

Gerald E. Commissiong

John W. Commissiong, M.D.

For more information, see this company's profile on OMP global database

View the management interview with Gerald Commissiong

NOTE: This summary was produced by OneMedPlace (OMP). Research based on information provided by the company and other sources.